Zobrazeno 1 - 10
of 681
pro vyhledávání: '"72"'
Publikováno v:
Journal of infection in developing countries. 13(11)
Introduction: This research aimed to determine the association of the combination of H. pylori infection and TP53 codon 72 polymorphism with non-cardia gastric cancer (GC) in Vietnam. Methodology: A total of 164 patients with non-cardia GC and 164 pa
Autor:
Sundaramoorthy Revathidevi, Kottayasamy Seenivasagam Rajkumar, Basant K. Tiwary, Vilvanathan Vinothkumar, Ganesan Arunkumar, Kanagaraj Arun, Ramamurthy Rajaraman, Arunagiri Kuha Deva Magendhra Rao, Mayakannan Manikandan, Arasambattu Kannan Munirajan
Publikováno v:
Gene Reports. 7:106-112
Background and aim Genetic susceptibility to cancer through single nucleotide polymorphisms - p53 Pro72Arg, p73 G4C14-A4T14 (two linked polymorphism) and MDM2 T309G has been reported in various ethnic populations. Yet the association is unclear in or
Autor:
Linyuan Qin, Xiaoqiang Qiu, Xiangyuan Yu, Hongping Yu, Songqing He, Bo Tang, Chunhua Bei, Yingchun Liu, Moqin Qiu, Xiaoyun Zeng
Publikováno v:
Tumor Biology. 37:3863-3870
The p53 tumor suppressor and its negative regulator, murine double minute 2 (MDM2), play critical roles in carcinogenesis. P53 codon 72 and MDM2 309T>G polymorphisms could influence p53 and MDM2 function, respectively, and might affect cancer suscept
Publikováno v:
Biomedical reports. 6(2)
The p53 tumor suppressor gene is key in tumor development and progression, and the single nucleotide polymorphism (SNP) of the p53 gene codon 72 (p53Arg/Pro) changes the structure of the protein. In addition, it affects its activity, which may affect
Autor:
Carolina Nunes França, M. R. Lisboa, Ismael Dale Cotrim Guerreiro da Silva, Joao Paulo Ferreira de Oliveira Kleine, Bruna Cristine de Almeida, C. M. Camargo-Kosugi, J. P. Franca
Publikováno v:
Genetics and molecular research : GMR. 15(1)
The association between TP53 gene polymorphisms and breast cancer (BC) in Brazilian women is a controversial topic. In this cross-sectional study, we evaluated the association between clinical pathological variables and three polymorphisms (TP53*11,
Breast cancer risk in relation to TP53 codon 72 and CDH1 gene polymorphisms in the Bangladeshi women
Autor:
Abul Hasnat, Samia Shabnaz, Md. Siddiqul Islam, Mir Md. Abdullah Al-Mamun, Md. Reazul Islam, Maizbha Uddin Ahmed, Mohammad Safiqul Islam
Publikováno v:
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 37(6)
Pharmacogenomic studies play a significant role in understanding the risk of breast cancer where genetic abnormalities are implicated as the etiology of cancer. Various polymorphisms of tumor suppressor gene TP53 and E-cadherin (CDH1) have been found
Publikováno v:
Europe PubMed Central
Aims A case-control study was performed to investigate the relationship between cervical cancer and TP53 polymorphism at codon 72 in young black African women from The Gambia. Materials and Methods The TP53 polymorphism at codon 72 was examined by PC
Publikováno v:
Medical Oncology (Northwood, London, England)
Human papilloma virus (HPV) is considered to be responsible for a large part of vaginal and vulvar carcinomas, and the p53 codon 72 polymorphism has been implicated in susceptibility to cancer induced by this virus, but with contradicting results. In
Autor:
Margarita Gerou, Benjamin A. Hall, Scott P. Allen, Kathrin Meyer, Pamela J. Shaw, Ryan Woof, Jessica Allsop, Stephen J. Kolb
Publikováno v:
Neurobiology of Aging
Highlights • Aging affects the metabolic profile of fibroblasts derived from ALS cases • Increased NADH metabolism with age is observed in the presence of a specific set of catabolic energy substrates in healthy individuals • Reduced NADH metab
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 11 (2020)
Frontiers in Pharmacology, Vol 11 (2020)
Pathological conditions such as joint immobilization, long-time bed rest, or inactivity may result in disuse-induced muscle wasting and dysfunction. To investigate the effect of dulaglutide, a long-acting glucagon-like peptide-1 receptor agonist, on